ARTICLE | Company News
Watson, Covidien neurology news
February 6, 2012 8:00 AM UTC
Watson and Covidien's Mallinckrodt Inc. subsidiary settled a December 2010 suit filed in the U.S. District Court for the District of New Jersey claiming that Watson infringed U.S. Patent No. 5,914,131 covering pain drug Exalgo hydromorphone. Under the settlement, Watson received a royalty-free license to U.S. patents relating to Exalgo and the right to launch its bioequivalent on Nov. 15, 2013. The '131 patent expires on July 7, 2014. Details were not disclosed (see BioCentury, Dec. 20, 2010). ...